Thermo Fisher Scientific (NYSE:TMO) Releases FY 2026 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 24.640-25.120 for the period, compared to the consensus estimate of 24.770. The company issued revenue guidance of $47.3 billion-$48.1 billion, compared to the consensus revenue estimate of $47.5 billion.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Robert W. Baird set a $653.00 target price on Thermo Fisher Scientific in a research report on Friday, January 30th. Evercore restated an “outperform” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Stifel Nicolaus boosted their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Finally, UBS Group reiterated a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $631.25.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $38.68 during midday trading on Thursday, reaching $475.31. 1,646,526 shares of the company traded hands, compared to its average volume of 2,256,323. The firm has a market cap of $176.63 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 2.72 and a beta of 0.97. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $643.99. The firm’s 50 day simple moving average is $500.69 and its two-hundred day simple moving average is $550.56.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the previous year, the firm posted $5.15 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts expect that Thermo Fisher Scientific will post 24.68 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.60%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.33% of the company’s stock.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results: EPS $5.44 and revenue $11.01B topped consensus (EPS and sales beats, revenue +6.2% y/y), supporting fundamentals and near-term earnings visibility. Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Analyst support: William Blair reiterated a Buy rating citing solid core growth and potential catalysts from AI adoption and reshoring — a vote of confidence that can sustain investor interest. Thermo Fisher Scientific: Buy Rating Reiterated on Solid Core Growth and Emerging AI, Reshoring Catalysts
• Positive Sentiment: Segment performance: Growth in Laboratory Products and Biopharma Services helped offset weakness elsewhere, underpinning the beat and recurring revenue streams. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Neutral Sentiment: Longer-term market tailwinds: digital lab transformation (Cloud ELN) and expanding microbiology testing markets present growth opportunities but are multi-year plays. Global Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation
• Neutral Sentiment: Analyst consensus: Street view remains constructive (consensus around Moderate Buy), which cushions downside but limits surprise upside absent stronger guidance. Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Rating of “Moderate Buy” by Analysts
• Negative Sentiment: Market reaction: shares slipped in premarket trading despite the beat, indicating profit-taking or that forward guidance/growth cadence disappointed some traders. Thermo Fisher slips in premarket despite beating Q1 forecasts
• Negative Sentiment: Product-line softness: analytical instruments and specialty diagnostics showed weakness—a risk to near-term growth if those trends persist. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors have recently bought and sold shares of the stock. JPL Wealth Management LLC bought a new position in Thermo Fisher Scientific during the third quarter valued at about $28,000. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. Birchwood Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Osterweis Capital Management Inc. increased its stake in shares of Thermo Fisher Scientific by 151.4% in the third quarter. Osterweis Capital Management Inc. now owns 88 shares of the medical research company’s stock worth $43,000 after purchasing an additional 53 shares during the period. Finally, Wealth Watch Advisors INC bought a new position in shares of Thermo Fisher Scientific in the third quarter worth about $44,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.